Intellia Therapeutics (NTLA) Net Cash Flow (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Net Cash Flow data on file, last reported at -$17.5 million in Q1 2026.

• Quarterly Net Cash Flow rose 68.01% year-over-year to -$17.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 105.12% YoY) and the FY2025 annual result came in at -$35.2 million, up 6.25% from the prior year.
• Net Cash Flow rose to -$17.5 million in Q1 2026 per NTLA's latest filing, from -$39.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $385.7 million in Q4 2022 and bottomed at -$229.4 million in Q1 2023.
• The 5-year median for Net Cash Flow is -$6.9 million (2022), against an average of $1.4 million.
• The widest annual swing landed in 2023, when Net Cash Flow tumbled 1629.85%; it then surged 459.45% in 2025.
• Tracing NTLA's Net Cash Flow over 5 years: stood at $385.7 million in 2022, then plunged by 84.61% to $59.4 million in 2023, then climbed by 15.7% to $68.7 million in 2024, then sank by 157.91% to -$39.8 million in 2025, then surged by 56.08% to -$17.5 million in 2026.
• Per Business Quant, the three latest NTLA Net Cash Flow figures stand at -$17.5 million (Q1 2026), -$39.8 million (Q4 2025), and $37.2 million (Q3 2025).

Peer Comparison